BioCentury | Oct 13, 2020
Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

...can be managed through careful dosing and monitoring.Omega Funds previously invested in rare disease play Wilson Therapeutics AB...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc. last year, and of Syntimmune Inc. and Wilson Therapeutics AB...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...rare autoimmune disease company Syntimmune Inc., and $855 million in cash to acquire Swedish biotech Wilson Therapeutics AB...
BioCentury | Sep 28, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

...This year, Alexion gained decuprate bis-choline tetrathiomolybdate (WTX101) through its $855 million cash acquisition of Wilson Therapeutics AB...
BioCentury | Sep 26, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

...This year, Alexion gained decuprate bis-choline tetrathiomolybdate (WTX101) through its $855 million cash acquisition of Wilson Therapeutics AB...
BioCentury | Aug 10, 2018
Company News

Management tracks: Oncopeptides, Merz

...He was CFO at medical software company RaySearch Laboratories AB (Stockholm, Sweden) as well as Wilson Therapeutics AB...
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...to von Emster, investments from that fund that have yielded double-digit returns include exits from Wilson Therapeutics AB...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...to von Emster, investments from that fund that have yielded double-digit returns include exits from Wilson Therapeutics AB...
...and leaves it with over $1.2 billion under management. Allison Johnson Abingworth Management Ltd. CRISPR Therapeutics AG IFM Therapeutics Inc. Wilson Therapeutics AB...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...June 19 and an MAA to EMA on June 28. Alexion also acquired Swedish biotech Wilson Therapeutics AB...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

...United Therapeutics Corp. (NASDAQ:UTHR) SteadyMed Ltd. (NASDAQ:STDY) 4/30/18 $141 $75 $216 Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Wilson Therapeutics AB...
Items per page:
1 - 10 of 40
BioCentury | Oct 13, 2020
Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

...can be managed through careful dosing and monitoring.Omega Funds previously invested in rare disease play Wilson Therapeutics AB...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc. last year, and of Syntimmune Inc. and Wilson Therapeutics AB...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...rare autoimmune disease company Syntimmune Inc., and $855 million in cash to acquire Swedish biotech Wilson Therapeutics AB...
BioCentury | Sep 28, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

...This year, Alexion gained decuprate bis-choline tetrathiomolybdate (WTX101) through its $855 million cash acquisition of Wilson Therapeutics AB...
BioCentury | Sep 26, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

...This year, Alexion gained decuprate bis-choline tetrathiomolybdate (WTX101) through its $855 million cash acquisition of Wilson Therapeutics AB...
BioCentury | Aug 10, 2018
Company News

Management tracks: Oncopeptides, Merz

...He was CFO at medical software company RaySearch Laboratories AB (Stockholm, Sweden) as well as Wilson Therapeutics AB...
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...to von Emster, investments from that fund that have yielded double-digit returns include exits from Wilson Therapeutics AB...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...to von Emster, investments from that fund that have yielded double-digit returns include exits from Wilson Therapeutics AB...
...and leaves it with over $1.2 billion under management. Allison Johnson Abingworth Management Ltd. CRISPR Therapeutics AG IFM Therapeutics Inc. Wilson Therapeutics AB...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...June 19 and an MAA to EMA on June 28. Alexion also acquired Swedish biotech Wilson Therapeutics AB...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

...United Therapeutics Corp. (NASDAQ:UTHR) SteadyMed Ltd. (NASDAQ:STDY) 4/30/18 $141 $75 $216 Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Wilson Therapeutics AB...
Items per page:
1 - 10 of 40